{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:13:06Z","timestamp":1792811586308,"version":"4.5.0"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"18","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C309\/A11566"],"award-info":[{"award-number":["C309\/A11566"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000537","name":"Breakthrough Breast Cancer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"European Investment Fund","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monopolar spindle 1 (MPS1) occupies a central role in mitosis and is one of the main components of the spindle assembly checkpoint. The MPS1 kinase is an attractive cancer target, and herein, we report the discovery of the clinical candidate BOS172722. The starting point for our work was a series of pyrido[3,4-d]pyrimidine inhibitors that demonstrated excellent potency and kinase selectivity but suffered from rapid turnover in human liver microsomes (HLM). Optimizing HLM stability proved challenging since it was not possible to identify a consistent site of metabolism and lowering lipophilicity proved unsuccessful. Key to overcoming this problem was the finding that introduction of a methyl group at the 6-position of the pyrido[3,4-d]pyrimidine core significantly improved HLM stability. Met ID studies suggested that the methyl group suppressed metabolism at the distant aniline portion of the molecule, likely by blocking the preferred pharmacophore through which P450 recognized the compound. This work ultimately led to the discovery of BOS172722 as a Phase 1 clinical candidate.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.8b00690","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T15:57:35Z","timestamp":1536595055000},"page":"8226-8240","source":"Crossref","is-referenced-by-count":33,"title":["Introduction of\na Methyl Group Curbs Metabolism of\nPyrido[3,4-\n                    <i>d<\/i>\n                    ]pyrimidine Monopolar Spindle\n1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical\nCandidate\n                    <i>N<\/i>\n                    2-(2-Ethoxy-4-(4-methyl-4\n                    <i>H<\/i>\n                    -1,2,4-triazol-3-yl)phenyl)-6-methyl-\n                    <i>N<\/i>\n                    8-neopentylpyrido[3,4-\n                    <i>d<\/i>\n                    ]pyrimidine-2,8-diamine (BOS172722)"],"prefix":"10.1021","volume":"61","author":[{"given":"Hannah L.","family":"Woodward","sequence":"first","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Innocenti","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwai-Ming J.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hayes","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Roberts","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Henley","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Faisal","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Wing-Yan","family":"Mak","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Box","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac M.","family":"Westwood","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]},{"name":"The Institute of Cancer Research , , ,","place":["London, United Kingdom, SW3 6JB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Cronin","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research , , ,","place":["London, United Kingdom, SW3 6JB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Carter","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Valenti","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"De Haven Brandon","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"O\u2019Fee","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Saville","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Burke","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Broccatelli","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob L. M.","family":"van Montfort","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]},{"name":"The Institute of Cancer Research , , ,","place":["London, United Kingdom, SW3 6JB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence I.","family":"Raynaud","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne A.","family":"Eccles","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiros","family":"Linardopoulos","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]},{"name":"The Institute of Cancer Research , , ,","place":["London, United Kingdom, SW3 6JB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-0323","authenticated-orcid":true,"given":"Julian","family":"Blagg","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8636-1488","authenticated-orcid":true,"given":"Swen","family":"Hoelder","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research , ,","place":["London, United Kingdom, SM2 5NG"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"2026090305381201500_cit1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-9525(97)01340-1","article-title":"The spindle\ncheckpoint","volume":"14","author":"Hardwick","year":"1998","journal-title":"Trends Genet."},{"key":"2026090305381201500_cit2","doi-asserted-by":"crossref","first-page":"16000","DOI":"10.1016\/S0021-9258(19)49633-6","article-title":"Expression of TTK,\na novel human protein kinase, is associated with\ncell proliferation","volume":"267","author":"Mills","year":"1992","journal-title":"J. Biol. Chem."},{"key":"2026090305381201500_cit3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/j.1460-2075.1995.tb07154.x","article-title":"Yeast spindle\npole body duplication gene MPS1 encodes an essential\ndual specificity protein kinase","volume":"14","author":"Lauze","year":"1995","journal-title":"EMBO J."},{"key":"2026090305381201500_cit4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrm2163","article-title":"The spindle-assembly\ncheckpoint in space and time","volume":"8","author":"Musacchio","year":"2007","journal-title":"Nat. Rev. Mol.\nCell Biol."},{"key":"2026090305381201500_cit5","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1073\/pnas.1007645108","article-title":"High levels\nof the MPS1 checkpoint protein are protective of aneuploidy in breast\ncancer cells","volume":"108","author":"Daniel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090305381201500_cit6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0107","article-title":"Functional\nviability profiles of breast cancer","volume":"1","author":"Brough","year":"2011","journal-title":"Cancer\nDiscovery"},{"key":"2026090305381201500_cit7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrg3123","article-title":"Causes and consequences of aneuploidy\nin cancer","volume":"13","author":"Gordon","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"2026090305381201500_cit8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/25292","article-title":"Genetic instabilities\nin human cancers","volume":"396","author":"Lengauer","year":"1998","journal-title":"Nature"},{"key":"2026090305381201500_cit9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng1861","article-title":"A signature\nof chromosomal instability inferred from gene expression profiles\npredicts clinical outcome in multiple human cancers","volume":"38","author":"Carter","year":"2006","journal-title":"Nat. Genet."},{"key":"2026090305381201500_cit10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/1078-0432.CCR-05-0903","article-title":"Increased\nexpression of mitotic checkpoint genes in breast cancer cells with\nchromosomal instability","volume":"12","author":"Yuan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2026090305381201500_cit11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/j.1349-7006.2008.00844.x","article-title":"Detection of novel\ncancer-testis antigen-specific T-cell responses in TIL, regional lymph\nnodes, and PBL in patients with esophageal squamous cell carcinoma","volume":"99","author":"Mizukami","year":"2008","journal-title":"Cancer Sci."},{"key":"2026090305381201500_cit12","doi-asserted-by":"publisher","first-page":"10148","DOI":"10.1158\/0008-5472.CAN-07-1887","article-title":"A cell proliferation\nand chromosomal instability signature\nin anaplastic thyroid carcinoma","volume":"67","author":"Salvatore","year":"2007","journal-title":"Cancer Res."},{"key":"2026090305381201500_cit13","first-page":"2492","article-title":"Identification of gene expression\npatterns in superficial and invasive human bladder cancer","volume":"61","author":"Thykjaer","year":"2001","journal-title":"Cancer Res."},{"key":"2026090305381201500_cit14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1158\/1535-7163.MCT-15-0500","article-title":"Novel MPS1\nkinase inhibitors with potent antitumor activity","volume":"15","author":"Wengner","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"2026090305381201500_cit15","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1073\/pnas.1700234114","article-title":"Functional characterization\nof CFI-402257, a potent and selective MPS1\/TTK kinase inhibitor, for\nthe treatment of cancer","volume":"114","author":"Mason","year":"2017","journal-title":"Proc. Natl. Acad. Sci.\nU. S. A."},{"key":"2026090305381201500_cit16","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.1021\/jm401395s","article-title":"Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of\nmitotic kinase monopolar spindle 1 (MPS1)","volume":"56","author":"Naud","year":"2013","journal-title":"J.\nMed. Chem."},{"key":"2026090305381201500_cit17","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1021\/acs.jmedchem.5b01811","article-title":"Rapid discovery of\npyrido[3,4-d]pyrimidine inhibitors of monopolar spindle\nkinase 1 (MPS1) using a structure-based hybridization approach","volume":"59","author":"Innocenti","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026090305381201500_cit18","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1158\/1535-7163.MCT-11-0453","article-title":"Characterization\nof the cellular and antitumor effects of MPI-0479605, a small-molecule\ninhibitor of the mitotic kinase MPS1","volume":"10","author":"Tardif","year":"2011","journal-title":"Mol. Cancer\nTher."},{"key":"2026090305381201500_cit19","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/jnci\/djt168","article-title":"Effects of\nthe selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity\nto antimitotic drugs","volume":"105","author":"Tannous","year":"2013","journal-title":"J. Natl. Canc. Inst."},{"key":"2026090305381201500_cit20","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.bmc.2015.02.042","article-title":"A unique hinge\nbinder of extremely selective aminopyridine-based MPS1 (TTK) kinase\ninhibitors with cellular activity","volume":"23","author":"Kusakabe","year":"2015","journal-title":"Bioorg. Med.\nChem."},{"key":"2026090305381201500_cit21","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.bmc.2014.06.027","article-title":"Discovery of inhibitors of the mitotic\nkinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides","volume":"22","author":"Laufer","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"2026090305381201500_cit22","doi-asserted-by":"publisher","first-page":"e0138616","DOI":"10.1371\/journal.pone.0138616","article-title":"Mitotic checkpoint\nkinase MPS1 has a role in normal physiology which impacts clinical\nutility","volume":"10","author":"Martinez","year":"2015","journal-title":"PLoS One"},{"key":"2026090305381201500_cit23","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1093\/annonc\/mdv293","article-title":"Inhibition\nof the spindle assembly\ncheckpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative\nbreast cancer model","volume":"26","author":"Maia","year":"2015","journal-title":"Ann. Oncol."},{"key":"2026090305381201500_cit24","unstructured":"Wengner, A. M.; Siemeister, G.\n          Combinations for\nthe Treatment of Cancer Comprising a MPS-1 Kinase Inhibitor and a\nMitotic Inhibitor. WO2014198645, 2014."},{"key":"2026090305381201500_cit25","unstructured":"Wengner, A. M.; Siemeister, G.\n          Combination\nof\na Imidazopyridazine Derivative and a Mitotic Agent for the Treatment\nof Cancer. WO2014198776A1, 2014."},{"key":"2026090305381201500_cit26","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1021\/jm501599u","article-title":"Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available\nMPS1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative\nactivity","volume":"58","author":"Kusakabe","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090305381201500_cit27","first-page":"106","article-title":"Current\napproaches in treatment of triple-negative\nbreast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol. Med."},{"key":"2026090305381201500_cit28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1039\/C4OB02238F","article-title":"Expanding the scope\nof fused pyrimidines as kinase inhibitor scaffolds: synthesis and\nmodification of pyrido[3,4-d]pyrimidines","volume":"13","author":"Innocenti","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"2026090305381201500_cit29","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1021\/jm049355+","article-title":"Pyrido[2,3-d]pyrimidin-7-ones\nas specific inhibitors of cyclin-dependent kinase 4","volume":"48","author":"VanderWel","year":"2005","journal-title":"J. Med. Chem."},{"key":"2026090305381201500_cit30","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery\nof a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J. Med. Chem."},{"key":"2026090305381201500_cit31","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines\nfor the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"2026090305381201500_cit32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/bjc.2017.75","article-title":"Characterisation of CCT271850, a selective, oral and\npotent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy","volume":"116","author":"Faisal","year":"2017","journal-title":"Br.\nJ. Cancer"},{"key":"2026090305381201500_cit33","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1021\/ci700018y","article-title":"New and original pka\nprediction method using grid molecular interaction fields","volume":"47","author":"Milletti","year":"2007","journal-title":"J. Chem. Inf. Model."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.8b00690","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/18\/8226\/67200344\/acs.jmedchem.8b00690.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/18\/8226\/67200344\/acs.jmedchem.8b00690.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:38:19Z","timestamp":1788428299000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/61\/18\/8226\/696594\/Introduction-of-a-Methyl-Group-Curbs-Metabolism-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":33,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2018,9,10]]},"published-print":{"date-parts":[[2018,9,27]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00690","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]}}}